These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 18080239)
1. Isolation and characterization of process related impurities of olanzapine using HPLC and ESI-MS/MS. Rao RN; Raju AN; Narsimha R; Babu GR J Sep Sci; 2008 Jan; 31(1):107-18. PubMed ID: 18080239 [TBL] [Abstract][Full Text] [Related]
2. Isolation and characterization of degradation products of citalopram and process-related impurities using RP-HPLC. Rao RN; Raju AN; Narsimha R J Sep Sci; 2008 Jun; 31(10):1729-38. PubMed ID: 18481321 [TBL] [Abstract][Full Text] [Related]
3. Development of a validated RP-LC/ESI-MS-MS method for separation, identification and determination of related substances of tamsulosin in bulk drugs and formulations. Nageswara Rao R; Kumar Talluri MV; Narasa Raju A; Shinde DD; Ramanjaneyulu GS J Pharm Biomed Anal; 2008 Jan; 46(1):94-103. PubMed ID: 17951020 [TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of process related impurities and degradation products of bicalutamide and development of RP-HPLC method for impurity profile study. Nageswara Rao R; Narasa Raju A; Narsimha R J Pharm Biomed Anal; 2008 Feb; 46(3):505-19. PubMed ID: 18162355 [TBL] [Abstract][Full Text] [Related]
5. Simultaneous separation and determination of process-related substances and degradation products of venlafaxine by reversed-phase HPLC. Nageswara Rao R; Narasa Raju A J Sep Sci; 2006 Dec; 29(18):2733-44. PubMed ID: 17305234 [TBL] [Abstract][Full Text] [Related]
6. RP-HPLC separation and ESI-MS, 1H, and 13C NMR characterization of forced degradants including process related impurities of carisbamate: method development and validation. Rao RN; Ramakrishna K; Sravan B; Santhakumar K J Pharm Biomed Anal; 2013 Apr; 77():49-54. PubMed ID: 23376724 [TBL] [Abstract][Full Text] [Related]
7. Separation, characterization, and quantitation of process-related substances of the anti-hypertensive drug doxazosin mesylate by reversed-phase LC with PDA and ESI-MS as detectors. Nageswara Rao R; Nagaraju D; Das AK; Jena N J Chromatogr Sci; 2007 Feb; 45(2):63-9. PubMed ID: 17425134 [TBL] [Abstract][Full Text] [Related]
9. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS. Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334 [TBL] [Abstract][Full Text] [Related]
10. RP-HPLC separation and characterization of unknown impurities of a novel HIV-protease inhibitor Darunavir by ESI-MS and 2D NMR spectroscopy. Nageswara Rao R; Ramachandra B; Santhakumar K J Pharm Biomed Anal; 2013 Mar; 75():186-91. PubMed ID: 23266664 [TBL] [Abstract][Full Text] [Related]
11. Development and validation of a stability indicating assay of doxofylline by RP-HPLC: ESI-MS/MS, ¹H and ¹³C NMR spectroscopic characterization of degradation products and process related impurities. Rao RN; Naidu ChG; Prasad KG; Santhakumar B; Saida S J Pharm Biomed Anal; 2013 May; 78-79():92-9. PubMed ID: 23466440 [TBL] [Abstract][Full Text] [Related]
13. Rapid separation and determination of process-related substances of paracetamol using reversed-phase HPLC with photo diode array as a detector. Rao RN; Narasaraju A Anal Sci; 2006 Feb; 22(2):287-92. PubMed ID: 16512424 [TBL] [Abstract][Full Text] [Related]
14. Development and validation of a systematic UPLC-MS/MS method for simultaneous determination of three phenol impurities in ritonavir. Venugopal N; Vijaya Bhaskar Reddy A; Madhavi G J Pharm Biomed Anal; 2014 Mar; 90():127-33. PubMed ID: 24366213 [TBL] [Abstract][Full Text] [Related]
15. Development and validation of a reversed-phase HPLC method for separation and simultaneous determination of process-related substances of mirtazapine in bulk drugs and formulations. Rao RN; Raju AN J Chromatogr Sci; 2009 Mar; 47(3):223-30. PubMed ID: 19298710 [TBL] [Abstract][Full Text] [Related]
16. Reversed-phase liquid chromatography with electrospray mass detection and 1H and 13C NMR characterization of new process-related impurities, including forced degradants of efavirenz: related substances correlated to the synthetic pathway. Gadapayale K; Kakde R; Sarma VU J Sep Sci; 2015 Jan; 38(2):218-30. PubMed ID: 25385054 [TBL] [Abstract][Full Text] [Related]
17. Impurity profile study of lopinavir and validation of HPLC method for the determination of related substances in lopinavir drug substance. Chitturi SR; Bharathi Ch; Reddy AV; Reddy KC; Sharma HK; Handa VK; Dandala R; Bindu VH J Pharm Biomed Anal; 2008 Dec; 48(5):1430-40. PubMed ID: 18947954 [TBL] [Abstract][Full Text] [Related]
18. Isolation, identification and characterization of two novel process-related impurities in olanzapine. Zhuang T; Zhang W; Cao L; He K; Wang Y; Li J; Chen L; Liu B; Zhang G J Pharm Biomed Anal; 2018 Apr; 152():188-196. PubMed ID: 29414012 [TBL] [Abstract][Full Text] [Related]
19. Separation and estimation of process-related impurities of gefitinib by reverse-phase high-performance liquid chromatography. Chandrashekara KA; Udupi A; Reddy CG J Chromatogr Sci; 2014 Sep; 52(8):799-805. PubMed ID: 23897663 [TBL] [Abstract][Full Text] [Related]
20. Simultaneous separation and determination of coenzyme Q(10) and its process related impurities by NARP-HPLC and atmospheric pressure chemical ionization-mass spectrometry (APCI-MS). Nageswara Rao R; Kumar Talluri MV; Shinde DD J Pharm Biomed Anal; 2008 Jun; 47(2):230-7. PubMed ID: 18243624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]